UNIVERSE PHARMACEUTICALS INC (UPC)
KYG9442G1120 - Common Stock
Taking everything into account, UPC scores 3 out of 10 in our fundamental rating. UPC was compared to 197 industry peers in the Pharmaceuticals industry. UPC scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. UPC does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
UPC had negative earnings in the past year.
UPC had a positive operating cash flow in the past year.
In multiple years UPC reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: UPC reported negative operating cash flow in multiple years.
1.2 Ratios
UPC has a better Return On Assets (-11.57%) than 72.82% of its industry peers.
UPC has a Return On Equity of -15.59%. This is in the better half of the industry: UPC outperforms 76.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -11.57% | ||
| ROE | -15.59% | ||
| ROIC | N/A |
ROA(3y)-3.37%
ROA(5y)11.69%
ROE(3y)-5.07%
ROE(5y)16.43%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 31.93%, UPC is in line with its industry, outperforming 53.85% of the companies in the same industry.
UPC's Gross Margin has declined in the last couple of years.
UPC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 31.93% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-11.39%
GM growth 5Y-7.46%
2. Health
2.1 Basic Checks
UPC does not have a ROIC to compare to the WACC, probably because it is not profitable.
UPC has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, UPC has more shares outstanding
Compared to 1 year ago, UPC has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 1.65, we must say that UPC is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.65, UPC is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
UPC has a debt to FCF ratio of 5.10. This is a neutral value as UPC would need 5.10 years to pay back of all of its debts.
UPC has a Debt to FCF ratio of 5.10. This is amongst the best in the industry. UPC outperforms 85.64% of its industry peers.
A Debt/Equity ratio of 0.14 indicates that UPC is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.14, UPC perfoms like the industry average, outperforming 45.13% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.14 | ||
| Debt/FCF | 5.1 | ||
| Altman-Z | 1.65 |
ROIC/WACCN/A
WACC6.53%
2.3 Liquidity
A Current Ratio of 2.68 indicates that UPC has no problem at all paying its short term obligations.
The Current ratio of UPC (2.68) is comparable to the rest of the industry.
A Quick Ratio of 2.43 indicates that UPC has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.43, UPC is in line with its industry, outperforming 45.13% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.68 | ||
| Quick Ratio | 2.43 |
3. Growth
3.1 Past
UPC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 29.45%, which is quite impressive.
UPC shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -19.51%.
Measured over the past years, UPC shows a small growth in Revenue. The Revenue has been growing by 2.53% on average per year.
EPS 1Y (TTM)29.45%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q48%
Revenue 1Y (TTM)-19.51%
Revenue growth 3Y1.72%
Revenue growth 5Y2.53%
Revenue growth Q2Q-13.16%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
UPC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Price/Free Cash Flow ratio of UPC indicates a rather cheap valuation: UPC is cheaper than 91.79% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.79 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
UPC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
UNIVERSE PHARMACEUTICALS INC
NASDAQ:UPC (5/17/2024, 7:00:01 PM)
2.59
+0.08 (+3.19%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap9.45M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -11.57% | ||
| ROE | -15.59% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 31.93% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.61
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.14 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.68 | ||
| Quick Ratio | 2.43 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)29.45%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next YN/A
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-19.51%
Revenue growth 3Y1.72%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y